Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

Abstract Background Entecavir (ETV) is recommended as a first-line anti-HBV treatment. However, many chronic hepatitis B patients initiate anti-HBV treatment such as lamivudine and telbivudine with low genetic barriers in China, which leads to compensatory mutations and increases the rate of ETV res...

Full description

Bibliographic Details
Main Authors: Jin Shang, Juan Zhou, Huan Liu, Rili M. Ise, You Tu, Jinqiu Ran, Lang Bai, Hong Tang
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Infectious Diseases
Subjects:
Hepatitis B virus
Chronic hepatitis B
Antiviral treatment
Entecavir
Tenofovir
Adefovir
Online Access:https://doi.org/10.1186/s12879-021-06554-1

Internet

https://doi.org/10.1186/s12879-021-06554-1

Similar Items